Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

about

Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

Item

http://www.wikidata.org/entity/Q46757500

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@en

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@nl

type

Item

label

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@en

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@nl

prefLabel

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@en

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@nl

P1476

Changes in Neuropsychiatric In ...... atment of Alzheimer's Disease.

@en

P2093

Anton P Porsteinsson

http://www.w3.org/2001/XMLSchema#string

Jacobo E Mintzer

http://www.w3.org/2001/XMLSchema#string

Nathan Herrmann

http://www.w3.org/2001/XMLSchema#string

Paul B Rosenberg

http://www.w3.org/2001/XMLSchema#string

Rema Raman

http://www.w3.org/2001/XMLSchema#string

Xiaoying Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment.

“Mini-mental state”

Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease

Development and validation of a geriatric depression screening scale: a preliminary report

Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review.

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

P304

373-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-151113

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Krista L Lanctôt

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27567808

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease